These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 19850631)
1. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I. Adam BW; Lim TH; Hall EM; Hannon WH Clin Chem; 2009 Dec; 55(12):2207-13. PubMed ID: 19850631 [TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836 [TBL] [Abstract][Full Text] [Related]
3. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs. De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104 [TBL] [Abstract][Full Text] [Related]
4. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine. Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492 [TBL] [Abstract][Full Text] [Related]
6. Performance of succinylacetone assays and their associated proficiency testing outcomes. Adam BW; Hall EM; Meredith NK; Lim TH; Haynes CA; De Jesus VR; Hannon WH Clin Biochem; 2012 Dec; 45(18):1658-63. PubMed ID: 22906829 [TBL] [Abstract][Full Text] [Related]
7. Laboratory monitoring of patients with hereditary tyrosinemia type I. Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364 [TBL] [Abstract][Full Text] [Related]
8. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program. Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696 [TBL] [Abstract][Full Text] [Related]
9. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy. Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233 [TBL] [Abstract][Full Text] [Related]
10. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819 [TBL] [Abstract][Full Text] [Related]
11. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Chace DH; Lim T; Hansen CR; De Jesus VR; Hannon WH Clin Chim Acta; 2009 Sep; 407(1-2):6-9. PubMed ID: 19545553 [TBL] [Abstract][Full Text] [Related]
12. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone. Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608 [TBL] [Abstract][Full Text] [Related]
13. Newborn screening for Tyr-I: two years' experience of the New York State program. Morrissey MA; Sunny S; Fahim A; Lubowski C; Caggana M Mol Genet Metab; 2011 Jun; 103(2):191-2. PubMed ID: 21441051 [TBL] [Abstract][Full Text] [Related]
14. Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process. Dhillon KS; Bhandal AS; Aznar CP; Lorey FW; Neogi P Clin Chim Acta; 2011 May; 412(11-12):873-9. PubMed ID: 21216241 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates. Lee B; Heo WY; Kim JA; Lee HS; Hwang N; Park HD; Sung SI; Chang YS; Park WS; Lee SY Ann Lab Med; 2023 Mar; 43(2):153-166. PubMed ID: 36281509 [TBL] [Abstract][Full Text] [Related]
16. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program. la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423 [No Abstract] [Full Text] [Related]
17. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry. Al-Dirbashi OY; Rashed MS; Brink HJ; Jakobs C; Filimban N; Al-Ahaidib LY; Jacob M; Al-Sayed MM; Al-Hassnan Z; Faqeih E J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):274-80. PubMed ID: 16384749 [TBL] [Abstract][Full Text] [Related]
18. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1]. Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637 [TBL] [Abstract][Full Text] [Related]
19. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Allard P; Grenier A; Korson MS; Zytkovicz TH Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530 [TBL] [Abstract][Full Text] [Related]
20. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS. Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]